A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients.

Trial Profile

A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Bempedoic acid (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 16 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 03 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Jan 2016 Status changed from planning to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top